Healthcare / Medical DevicesNasdaqGM
$0.52
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-16.3M · quality 49.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
4/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$2M
P/E
N/A
•EV/EBITDA
N/A
•ROE
134.4%
↑Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.45x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-35.8M · FCF $-16.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | — | — | $100000.00 | — | — | — |
| Net Income | $-35.8M | $-35.8M | $-9.2M | $1.2M | $7.2M | — |
| EPS | -107.01 | -107.01 | -357.14 | 0.12 | 0.30 | — |
| Operating Margin | — | — | -4500.0% | — | — | — |
| Net Margin | — | — | -9230.0% | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-16.3M | $-16.3M | — | — | — | — |
| Returns | ||||||
| ROE | 134.4% | 134.4% | 7.7% | -1.1% | -1157.1% | — |
| Growth & Yield | ||||||
| EPS Growth | 70.0% | 70.0% | -297716.7% | -60.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.